Home
  • E-mailRolf.Bjerkvig@uib.no
  • Phone+47 55 58 63 52+47 951 18 268
  • Visitor Address
    Jonas Lies vei 91
  • Postal Address
    Postboks 7804
    5020 Bergen

Rolf Bjerkvig (f. 1953) is Professor for cell biology and has since the ealy 80s worked in experimental cancer biology.

Dr Bjerkvig receives major grants from the Norwegian Research Council, The Norwegian Cancer Society and the European Commission. He is on the editorial board on several international journals and is sitting in several national as well as international funding committees for cancer research in Europe. He has published more than 200 articles in scientific literature and has received a number of research prizes for his work. In 2015, Bjerkvig was awarded the King Olav V Research Prize in Cancer Research.

OD1ANA - Anatomy

MEDOD1, MEDOD2

MEIBM900

FARM260 - Molecular cell biology

BMED330 - intercellular communication

BMED331 - tumor biology

  • Show author(s) 2020. Tumor-penetrating peptide for systemic targeting of Tenascin-C. Scientific Reports.
  • Show author(s) 2020. Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects. Neuro-Oncology Advances (NOA).
  • Show author(s) 2020. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. Acta Neuropathologica. 1-31.
  • Show author(s) 2020. Identification of a Blood-Based Protein Biomarker Panel for Lung Cancer Detection. Cancers.
  • Show author(s) 2020. AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives Glioblastoma invasion. Nature Communications.
  • Show author(s) 2019. Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma. EMBO Molecular Medicine.
  • Show author(s) 2019. Peptide-guided nanoparticles for glioblastoma targeting. Journal of Controlled Release. 109-118.
  • Show author(s) 2019. Long Noncoding RNA SChLAP1 Forms a Growth-Promoting Complex with HNRNPL in Human Glioblastoma through Stabilization of ACTN4 and Activation of NF-kappa B Signaling. Clinical Cancer Research. 6868-6881.
  • Show author(s) 2019. Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood-brain barrier. Molecular Cancer Therapeutics. 2171-2181.
  • Show author(s) 2019. Effective treatment of metastatic melanoma by combining mapk and pi3k signaling pathway inhibitors. International Journal of Molecular Sciences. 1-19.

More information in national current research information system (CRIStin)

1987: Dr. philos. The Gade Institute of Pathology, University of Bergen
1981: M.Sc. Immunology, University of San Francisco, 1981.

Fields of competence